Period 1 (2005) | Period 2 (2006–2008) | pvalue | |
---|---|---|---|
Cohort patients | |||
Bacteremia due to Cip-R organisms* | 3.02 | 6.77 | 0.03 |
Cip-R enterobacteria | 0.38 | 2.12 | 0.06 |
Cip-R Pseudomonas aeruginosa | 0.38 | 0.63 | 0.71 |
ESBL production | 0.38 | 1.27 | 0.26 |
Cip-R Staphylococcus aureus | 0 | 0.63 | 0.26 |
Cip-R CONS | 2.27 | 2.75 | 0.72 |
Non-cohort patients in the hematology unit | |||
Cip-R enterobacteria | 0.53 | 2.54 | 0.004 |
Cip-R Pseudomonas aeruginosa | 0.70 | 0.32 | 0.39 |
ESBL production | 0.52 | 1.59 | 0.08 |
Cip-R Staphylococcus aureus | 0 | 0.16 | 0.52 |
Cip-R CONS | 2.64 | 2.23 | 0.65 |
Hospital | |||
Cip-R enterobacteria | 0.76 | 0.64 | 0.15 |
Cip-R Pseudomonas aeruginosa | 0.22 | 0.21 | 0.78 |
ESBL production | 0.56 | 0.53 | 0.74 |
Cip-R Staphylococcus aureus | 0.33 | 0.23 | 0.06 |
Cip-R CONS | 0.68 | 0.60 | 0.33 |